Skye Bioscience, Inc.
SKYE
$2.23
$0.3518.62%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.79M | -12.51M | -14.44M | -12.75M | -17.62M |
| Total Depreciation and Amortization | 157.60K | 172.90K | 180.00K | 178.90K | 187.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.93M | 1.50M | 1.44M | 1.82M | 1.94M |
| Change in Net Operating Assets | -1.43M | 2.27M | 3.06M | -2.61M | 4.75M |
| Cash from Operations | -7.12M | -8.56M | -9.77M | -13.36M | -10.75M |
| Capital Expenditure | -- | -- | 0.00 | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | 178.20K | 900.00 | 180.00K | 91.40K | 89.40K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.96M | 10.90M | -2.98M | 7.88M | -11.94M |
| Cash from Investing | 7.14M | 10.90M | -2.80M | 7.97M | -11.86M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -107.30K | -71.50K | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 6.30K | -- | 11.40K | 0.00 | 18.20K |
| Cash from Financing | -101.00K | -71.50K | 11.40K | 0.00 | 18.20K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -80.70K | 2.27M | -12.56M | -5.40M | -22.58M |